Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 251 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/11/2007 First Published: 2/1/2000


1.		Phase II/III Randomized Study of Processed Versus Unprocessed Unrelated Bone Marrow Transplantation in Patients With Acute or Chronic Leukemia or Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care, Treatment				Completed				12 to 50				Other				CHIMERIC-HM01 WSU-10-02-99-M01-FB, NCT00004255

Last Modified: 5/1/1998


2.		Phase III Randomized Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) vs Fludarabine (FAMP) for Pretreated B-Cell Chronic Lymphocytic Leukemia (Summary Last Modified 05/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 79								EORTC-06942

Last Modified: 12/12/2008 First Published: 8/1/1996


3.		Phase III Randomized Study of Intensively Timed Induction Chemotherapy Followed By Consolidation With the Same Chemotherapy Versus Fludarabine, Cytarabine, and Idarubicin, Followed By Intensification With Either High-Dose Cytarabine and Asparaginase With or Without Subsequent Interleukin-2 or Allogeneic Bone Marrow Transplantation in Children With Previously Untreated Acute Myelogenous Leukemia or Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				Under 22				NCI				COG-2961 CCG-2961, NCT00002798

Last Modified: 5/11/2007 First Published: 3/1/1999


4.		Phase III Randomized Study of Fludarabine With or Without Cyclophosphamide in Patients With Previously Untreated Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-2997 CALGB-10103, SWOG-E2997, NCT00003764, E2997

Last Modified: 11/20/2008 First Published: 2/1/2000


5.		Phase III Randomized Study of Chlorambucil Alone Versus Fludarabine With or Without Cyclophosphamide in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				Other				LRF-CLL4 LRG-MRC-LEUK-CLL4, EU-99030, MRC-LEUK-CLL4, NCT00004218, EUDRACT-58585610, ISRCTN58585610

Last Modified: 7/11/2007 First Published: 6/1/2000


6.		Phase III Randomized Study of Induction Chemotherapy With Cytarabine, Daunorubicin, and Etoposide Versus Fludarabine and Cytarabine and Induction Chemotherapy With Versus Without Filgrastim (G-CSF) or Tretinoin in Patients With High Risk Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				MRC-LEUK-AML-HR EU-20008, NCT00005863

Last Modified: 1/4/2008 First Published: 9/1/2000


7.		Phase III Randomized Study of Chlorambucil, Mitoxantrone, and Dexamethasone Versus Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Newly Diagnosed Stage III or IV Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 70				Other				BNLI-MCD/FMD EU-20035, NCT00006250

Last Modified: 6/10/2004 First Published: 6/1/2001


8.		Phase III Randomized Study of Chlorambucil in Patients With B-Cell Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75				Other				EORTC-06992-CLL-3 NCT00017108

Last Modified: 2/17/2007 First Published: 9/1/2001


9.		Phase III Randomized Study of Fludarabine and Cyclophosphamide With or Without Oblimersen (G3139, Genasense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Over 18				Pharmaceutical / Industry				GENTA-GL303 UCLA-0104008, NCT00024440

Last Modified: 12/5/2007


10.		Phase III Comparison of CLB vs FAMP in Previously Untreated Patients with Intermediate- and High-Risk (Rai Stages I-IV) B-Cell CLL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				CLB-9011 CAN-NCIC-CL1, E-C9011, SWOG-9108, CALGB-9011, CL1

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute